ADMA — ADMA Biologics Inc stock price and chart

Share this page

ADMA

$10.68-0.47%

as of close, Oct 16, 2026

☾ AH $10.68 -0.47%

ADMA Biologics IncStock · HealthcareRussell 2000 0.06%Nasdaq Composite 0.005%Russell 3000 0.003%US Stock Market 0.003%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

2.04.06.08.010.012.014.016.018.020.022.00100.0M200.0M$10.68

2026-10-16

Price$10.68

MA20$9.18

MA50$13.06

Vol16.9M

What would $1,000 invested in ADMA be worth today? →

ADMA returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $10.68
YTD price return: -41.45%
YTD total return: -41.45%
Next earnings: Nov 4, 2026
Market cap: 2.4B2016-12 66M2026-10 2.4B+3529.0% over the window
Enterprise value: 2.5B
Shares outstanding: 224M2016-06 12.9M2026-06 224M+1638.1% over the window
52W low: $7.21
52W high: $20.46
From 52W high: -47.80%
From 52W low: +48.13%
52W range: 26%

Volume

Rel volume: 0.98×
30D volume: 3.1M
30D $ vol: 30.5M

Fundamentals

Sales (ttm): 512.3M2016-06 8.8M2026-06 512.3M+5747.7% over the window
Sales/share: $2.292016-06 $0.682026-06 $2.29+236.4% over the window
EPS (ttm): $0.712020-06 -$0.712026-06 $0.71-199.2% over the window
FCF (ttm): 116.5M2016-06 -16.8M2026-06 116.5M-793.9% over the window
FCF/share: $0.522016-06 -$1.302026-06 $0.52-139.9% over the window
Book value/share: $1.822016-06 $0.302026-06 $1.82+499.7% over the window
Net margin: 32.98%2016-06 -231.8%2026-06 33.0%-114.2% over the window
ROE: 41.39%2016-06 -518.6%2026-06 41.4%-108.0% over the window
ROA: 24.69%2016-06 -64.0%2026-06 24.7%-138.6% over the window
Debt / equity: 0.47×2017-06 0.062026-06 0.47+630.6% over the window
Current ratio: 6.972016-06 5.802026-06 6.97+20.1% over the window

Growth (CAGR, ttm) · 10Y

Sales: +8.04%2025-06-30 → 2026-06-30474.2M → 512.3M (+8.0% total)+35.01%2023-06-30 → 2026-06-30208.1M → 512.3M (+146.2% total)+54.55%2021-06-30 → 2026-06-3058.1M → 512.3M (+781.5% total)+50.22%2016-06-30 → 2026-06-308.8M → 512.3M (+5747.7% total)
Net income: -19.14%2025-06-30 → 2026-06-30208.9M → 169M (-19.1% total)n/an/an/a
FCF: +77.15%2025-06-30 → 2026-06-3065.8M → 116.5M (+77.1% total)n/an/an/a
Shares: -6.14%2025-06-30 → 2026-06-30238.6M → 224M (-6.1% total)-0.14%2023-06-30 → 2026-06-30224.9M → 224M (-0.4% total)+11.03%2021-06-30 → 2026-06-30132.8M → 224M (+68.7% total)+33.05%2016-06-30 → 2026-06-3012.9M → 224M (+1638.1% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -16.78%2025-06-30 → 2026-06-30$0.85 → $0.71 (-16.8% total)n/an/an/a
Sales/share: +15.11%2025-06-30 → 2026-06-30$1.99 → $2.29 (+15.1% total)+35.20%2023-06-30 → 2026-06-30$0.93 → $2.29 (+147.2% total)+39.20%2021-06-30 → 2026-06-30$0.44 → $2.29 (+422.5% total)+12.90%2016-06-30 → 2026-06-30$0.68 → $2.29 (+236.4% total)
FCF/share: +88.74%2025-06-30 → 2026-06-30$0.28 → $0.52 (+88.7% total)n/an/an/a
Book value/share: +9.19%2025-06-30 → 2026-06-30$1.67 → $1.82 (+9.2% total)+40.82%2023-06-30 → 2026-06-30$0.65 → $1.82 (+179.3% total)+16.74%2021-06-30 → 2026-06-30$0.84 → $1.82 (+116.8% total)+19.62%2016-06-30 → 2026-06-30$0.30 → $1.82 (+499.7% total)
Price: -26.66%2025-10-16 → 2026-10-16$14.56 → $10.68 (-26.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+46.73%2023-10-16 → 2026-10-16$3.38 → $10.68 (+216.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+57.53%2021-10-15 → 2026-10-16$1.10 → $10.68 (+870.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+5.27%2016-10-14 → 2026-10-16$6.39 → $10.68 (+67.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -26.66%2025-10-16 → 2026-10-16$14.56 → $10.68 (-26.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+46.73%2023-10-16 → 2026-10-16$3.38 → $10.68 (+216.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+57.53%2021-10-15 → 2026-10-16$1.10 → $10.68 (+870.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+5.27%2016-10-14 → 2026-10-16$6.39 → $10.68 (+67.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 15.1×2016-12 -3.382026-10 14.17-519.7% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 10.7×2016-12 -3.772026-10 10.67-383.2% over the window
Fwd P/E: 10.9×
P/S (ttm)Market cap ÷ TTM revenue.: 4.7×2016-12 6.702026-10 4.67-30.3% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 5.9×2016-12 -433.682026-10 5.87-101.4% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 20.5×2016-12 -3.512026-10 20.56-685.5% over the window
EV/EBITDA (fy): 10.6×
EV/Sales (ttm): 4.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.87%2016-09 -28.5%2026-06 6.2%-121.8% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 224.0M ÷ 238.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 6.14%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (6.14%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($4.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 6.14%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($187.2M) ÷ today's market cap ($2.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 7.82%2016-09 -19.6%2026-06 10.0%-151.1% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $187.2M + TTM dividends $0) ÷ today's market cap ($2.4B). Same caveat as the cash buyback yield.: 7.82%2016-09 -19.6%2026-06 10.0%-151.1% over the window

Vs own 10Y history

P/OI: 16th
P/S: 31st
P/B: 53rd

Bar = where today’s multiple sits in ADMA’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-0.47%

+3.09%

+20.00%

+21.23%

YTD

-41.45%

-26.65%

+870.91%

Financial statements

Open full ADMA financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

ADMA — ADMA Biologics Inc price, chart and key statistics